肌肉痉挛影响指数:以患者为中心的痉挛评估量表
本研究开发并验证了肌肉痉挛影响指数(MCII),用于评估肌肉痉挛的多维度影响。研究纳入105例患者,最终形成14条目量表(0-42分),包含痉挛频率/分布、睡眠干扰和日常生活干扰三个域,重测信度优秀(ICC 0.83)。
要点
- MCII为14条目患者报告结局量表,覆盖痉挛频率/分布、睡眠干扰和日常生活干扰。
- 量表与睡眠、情绪、疼痛和生活质量等既有量表呈中度相关,重测信度ICC 0.83。
- 适用于神经肌肉、ALS、肝病和肾病等多病因痉挛患者,但需进一步验证反应度。
核心结论
- MCII是以患者为中心、心理测量学稳健的工具,可捕获肌肉痉挛的多维度影响。
研究设计与样本
- 多中心前瞻性量表开发与验证研究,2018-2022年在神经肌肉、ALS、肝病和肾病门诊开展。
- 共105例患者完成现场测试,女性占40%,平均年龄60.0±14.2岁。
主要发现
- 18个草稿条目经患者和专家评审后精简为16条,探索性因子分析识别3个域。
- 因地板效应或低因子载荷删除2条,最终形成14条目量表,评分范围0-42分。
- MCII与EuroQol 5 Dimension、Epworth嗜睡量表、Beck抑郁量表和睡眠干扰评分呈中度相关。
- 重测信度优秀(n=57;ICC 0.83,95% CI 0.72-0.89)。
关键数值与推荐
- 所有条目缺失率低(<6%)。
- 内容效度经27名国际神经肌肉和肌肉痉挛专家评审。
- 最终量表包含3个域:痉挛频率/分布、睡眠干扰、日常生活干扰。
临床怎么用
- 可用于评估不同病因肌肉痉挛患者的多维度影响,辅助临床决策。
- 量表评分范围0-42分,涵盖频率/分布、睡眠和日常生活三个维度。
局限性
- 依赖患者自报临床稳定性。
- 邮寄问卷无法核实受访者身份。
- 需进一步评估反应度并在其他痉挛人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Muscle cramps are common, variably disabling, and lack a comprehensive validated tool to assess their multidimensional effect. Previous cramp studies have relied primarily on cramp frequency and intensity, despite qualitative work demonstrating that sleep disturbance, daytime functioning, and mental health are also important to patients. Guided by these findings, the aim of this study was to develop and validate a patient-reported outcome measure, the Muscle Cramp Impact Index (MCII), to assess the effect of muscle cramps across diverse etiologies and clinical settings. METHODS: This was a multisite, prospective scale-development and validation study conducted in neuromuscular, amyotrophic lateral sclerosis, hepatology, and kidney clinics at the University Health Network/Mount Sinai Hospital and Sunnybrook Health Sciences Centre (2018-2022). MCII item generation was based on a previous qualitative study, literature review, and cognitive interviews with affected patients. Content validity was assessed through review by 27 international neuromuscular and muscle cramp experts. Adult patients experiencing muscle cramps within the preceding 2 weeks were enrolled. Draft items were evaluated for missing data, floor/ceiling effects, and exploratory factor analysis (EFA). Test-retest reliability was assessed in clinically stable patients over a 2-week interval using weighted κ and intraclass correlation coefficients (ICCs). Construct validity was examined through predefined hypotheses correlating MCII scores with established measures of sleep disturbance, mood, pain, stiffness, and quality of life. RESULTS: A total of 105 patients (40% female individuals; mean age 60.0 ± 14.2 years) completed the field testing. Eighteen draft items were refined to 16 after patient and expert review. All items demonstrated low missingness (<6%). EFA identified 3 domains-cramp frequency/distribution, sleep interference, and interference with daily life-and 2 items were removed for floor effects or low factor loadings, yielding a final 14-item measure (score range 0-42). The MCII demonstrated moderate correlations with EuroQol 5 Dimension, Epworth Sleepiness Scale, Beck Depression Inventory, and Sleep Disturbance scores. Test-retest reliability was excellent (n = 57; ICC 0.83, 95% CI 0.72-0.89), confirming strong measurement stability. DISCUSSION: The MCII is a patient-centered, psychometrically robust measure capturing the multidimensional effect of muscle cramps. Limitations include reliance on self-reported clinical stability and inability to verify respondent identity for mailed questionnaires. Further evaluation of responsiveness and validation in additional cramp populations is warranted to support broader implementation.
引用
- Katzberg HD, Bril V, Zinman L, et al. The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps. Neurology. 2026. PMID: 41955555. doi:10.1212/WNL.0000000000214835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。